Dezecapavir vs Lenacapavir (Yeztugo)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HIV

Shared mechanism: HIV capsid · full HIV pipeline

Dezecapavir

Developed by ViiV Healthcare

Phase 2 in HIVsmall molecule
Partial signal

NCT06039579 · Phase 2 · completed

This Phase 2 trial was randomized, double-blind (participant and investigator), and placebo-controlled, with 44 participants allocated across multiple dose groups of VH4004280 and VH4011499. The primary endpoint was the maximum change in plasma HIV-1 RNA during 10-day monotherapy; posted results for VH4011499 show mean declines of about -1.8 to -2.2 log10 in active arms versus -0.18 log10 in placebo, but no p-values or confidence intervals are reported. Because the groups are very small (6-7 active vs 3 placebo) and the statistical significance of the primary comparison is not documented, this constitutes real but limited evidence.

Next expected readout: February 2027 · NCT07934719 (registry estimate)

Reported efficacy

Monotherapy, VH4011499: Maximum Change From Baseline (Day 1) in Plasma HIV-1 RNA log10 (From Baseline (Day 1) and up to Day 11): Monotherapy, VH4011499: Maximum Change From Baseline (Day 1) in Plasma HIV-1 RNA log10 (From Baseline (Day 1) and up to Day 11): Part 1b: VH4011499 Dose Level 1 — Baseline (Day 1): 5.001 log10 c/mL (Standard Deviation 0.7304); Maximum change compared to Baseline (Day 1): -1.834 log10 c/mL (Standard Deviation 0.5141) | Part 1b: VH4011499 Dose Level 2 — Baseline (Day 1): 4.339 log10 c/mL (Standard Deviation 0.6185); Maximum change compared to Baseline (Day 1): -1.797 log10 c/mL (Standard Deviation 0.4544) | Part 2b: VH4011499 Pre-specified Dose — Baseline (Day 1): 4.96 log10 c/mL (Standard Deviation 0.7288); Maximum change compared to Baseline (Day 1): -2.165 log10 c/mL (Standard Deviation 0.431) vs Matching Placebo for VH4011499 — Baseline (Day 1): 4.714 log10 c/mL (Standard Deviation 0.7736); Maximum change compared to Baseline (Day 1): -0.176 log10 c/mL (Standard Deviation 0.1969) (unclear)

Result source: NCT06039579

Lenacapavir (Yeztugo)

Marketed by Gilead Sciences

Approved in HIVsmall molecule
Reliable signal

NCT04994509 · Phase 3 · active, not recruiting

This is a very large randomized, double-blind trial with active-control arms and a hard primary endpoint, HIV-1 infection. Lenacapavir's HIV incidence was far below the background rate and met the prespecified superiority tests. The primary comparison is against a background rate estimated from screened participants, not directly against the control arms.

Next expected readout: March 2027 · NCT07210125 (registry estimate)

Reported efficacy

Incidence Phase: Recent Infection Testing Algorithm (RITA) Estimate of the Background Human Immunodeficiency-1 Virus Infection Incidence Rate (bHIV) Per 100 Person Years (PY) (Incidence Phase Screening Visit (Day 1)); Randomized Blinded Phase: HIV-1 Incidence Reported Per 100 PY for LEN Compared to Background HIV (bHIV, Participants in All Screened Set) (Up to 149 weeks): HIV incidence: 0.10 per 100 PY on twice-yearly lenacapavir (2 infections) vs background incidence 2.37 per 100 PY (IRR 0.04; 95% CI 0.01-0.18; P<0.001) and vs F/TDF 0.93 per 100 PY (IRR 0.11; 95% CI 0.02-0.51; P=0.002) (PURPOSE 2, NEJM 2025). (met)

Result source: NCT04925752

Results for HIV

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.

Key endpointDezecapavirLenacapavir (Yeztugo)
HIV-1 RNA below 50 copies/mL (week 48)—Not reported—Trial running · NCT04925752
HIV-1 RNA 50 copies/mL or more (week 48)—Not reported—Trial running · NCT04925752
CD4 count, change (week 48)—Not reported—Trial running · NCT04925752

HIV-1 RNA below 50 copies/mL (week 48)

Dezecapavir
—Not reported
Lenacapavir (Yeztugo)
—Trial running · NCT04925752

HIV-1 RNA 50 copies/mL or more (week 48)

Dezecapavir
—Not reported
Lenacapavir (Yeztugo)
—Trial running · NCT04925752

CD4 count, change (week 48)

Dezecapavir
—Not reported
Lenacapavir (Yeztugo)
—Trial running · NCT04925752
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Dezecapavir: 3 of 4 rows · Lenacapavir (Yeztugo): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricDezecapavirLenacapavir (Yeztugo)
Dropout rate
0%Dose Level 1a
NCT06039579 · Phase 2 · combination · HIV · phase 2
show 17 more results
—Dose Level 1
NCT06039579 · Phase 2 · combination · HIV · phase 2
—Dose Level 1
NCT06039579 · Phase 2 · monotherapy · HIV · phase 2
0%Dose Level 2
NCT06039579 · Phase 2 · combination · HIV · phase 2
—Dose Level 2
NCT06039579 · Phase 2 · combination · HIV · phase 2
—Dose Level 2
NCT06039579 · Phase 2 · monotherapy · HIV · phase 2
0%Pre-specified Dose
NCT06039579 · Phase 2 · combination · HIV · phase 2
—Pre-specified Dose
NCT06039579 · Phase 2 · combination · HIV · phase 2
—Pre-specified Dose
NCT06039579 · Phase 2 · monotherapy · HIV · phase 2
0%1875 mg PiB
NCT05393271 · Phase 1 · monotherapy
0%625 mg PiB
NCT05393271 · Phase 1 · monotherapy
0%400 mg PiB
NCT05393271 · Phase 1 · monotherapy
0%300 mg + Midazolam (MDZ) PiB
NCT05393271 · Phase 1 · combination
0%200 mg PiB
NCT05393271 · Phase 1 · monotherapy
0%200 mg PiB
NCT05393271 · Phase 1 · monotherapy
0%200 mg Tablet
NCT05393271 · Phase 1 · monotherapy
0%125 mg PiB
NCT05393271 · Phase 1 · monotherapy
0%25 mg PiB
NCT05393271 · Phase 1 · monotherapy
11.5%
NCT04994509 · Phase 3 · combination · HIV · phase 3
show 1 more result
94.4%
NCT04925752 · Phase 3 · combination · HIV · phase 3
Discontinued due to AEs
—Dose Level 1a
NCT06039579 · Phase 2 · combination · HIV · phase 2
show 17 more results
—Dose Level 1
NCT06039579 · Phase 2 · combination · HIV · phase 2
—Dose Level 1
NCT06039579 · Phase 2 · monotherapy · HIV · phase 2
—Dose Level 2
NCT06039579 · Phase 2 · combination · HIV · phase 2
—Dose Level 2
NCT06039579 · Phase 2 · combination · HIV · phase 2
—Dose Level 2
NCT06039579 · Phase 2 · monotherapy · HIV · phase 2
—Pre-specified Dose
NCT06039579 · Phase 2 · combination · HIV · phase 2
—Pre-specified Dose
NCT06039579 · Phase 2 · combination · HIV · phase 2
—Pre-specified Dose
NCT06039579 · Phase 2 · monotherapy · HIV · phase 2
—1875 mg PiB
NCT05393271 · Phase 1 · monotherapy
—625 mg PiB
NCT05393271 · Phase 1 · monotherapy
—400 mg PiB
NCT05393271 · Phase 1 · monotherapy
—300 mg + Midazolam (MDZ) PiB
NCT05393271 · Phase 1 · combination
—200 mg PiB
NCT05393271 · Phase 1 · monotherapy
—200 mg PiB
NCT05393271 · Phase 1 · monotherapy
—200 mg Tablet
NCT05393271 · Phase 1 · monotherapy
—125 mg PiB
NCT05393271 · Phase 1 · monotherapy
—25 mg PiB
NCT05393271 · Phase 1 · monotherapy
0.1%
NCT04994509 · Phase 3 · combination · HIV · phase 3
show 1 more result
0.2%
NCT04925752 · Phase 3 · combination · HIV · phase 3
Serious AEs
—Dose Level 1a
NCT06039579 · Phase 2 · combination · HIV · phase 2
show 17 more results
0%Dose Level 1
NCT06039579 · Phase 2 · combination · HIV · phase 2
0%Dose Level 1
NCT06039579 · Phase 2 · monotherapy · HIV · phase 2
—Dose Level 2
NCT06039579 · Phase 2 · combination · HIV · phase 2
0%Dose Level 2
NCT06039579 · Phase 2 · combination · HIV · phase 2
0%Dose Level 2
NCT06039579 · Phase 2 · monotherapy · HIV · phase 2
—Pre-specified Dose
NCT06039579 · Phase 2 · combination · HIV · phase 2
0%Pre-specified Dose
NCT06039579 · Phase 2 · combination · HIV · phase 2
0%Pre-specified Dose
NCT06039579 · Phase 2 · monotherapy · HIV · phase 2
0%1875 mg PiB
NCT05393271 · Phase 1 · monotherapy
0%625 mg PiB
NCT05393271 · Phase 1 · monotherapy
0%400 mg PiB
NCT05393271 · Phase 1 · monotherapy
0%300 mg + Midazolam (MDZ) PiB
NCT05393271 · Phase 1 · combination
0%200 mg PiB
NCT05393271 · Phase 1 · monotherapy
0%200 mg PiB
NCT05393271 · Phase 1 · monotherapy
0%200 mg Tablet
NCT05393271 · Phase 1 · monotherapy
0%125 mg PiB
NCT05393271 · Phase 1 · monotherapy
0%25 mg PiB
NCT05393271 · Phase 1 · monotherapy
3.8%
NCT04994509 · Phase 3 · combination · HIV · phase 3
show 1 more result
3.3%
NCT04925752 · Phase 3 · combination · HIV · phase 3
Most frequent reported AEs
Dose Level 1a
influenza 14.3% (placebo 33.3%)
proteinuria 14.3% (placebo 0%)
rash 14.3% (placebo 0%)
NCT06039579 · Phase 2 · combination · HIV · phase 2
show 14 more results
Dose Level 1
headache 14.3% (placebo 0%)
upper respiratory tract infection 14.3% (placebo 0%)
alanine aminotransferase increased 0% (placebo 0%)
NCT06039579 · Phase 2 · monotherapy · HIV · phase 2
Dose Level 2
arthralgia 16.7% (placebo 0%)
dermatophytosis 16.7% (placebo 0%)
ear pain 16.7% (placebo 0%)
NCT06039579 · Phase 2 · combination · HIV · phase 2
Dose Level 2
asthenia 16.7% (placebo 0%)
dermatitis acneiform 16.7% (placebo 0%)
diarrhoea 16.7% (placebo 0%)
NCT06039579 · Phase 2 · monotherapy · HIV · phase 2
Pre-specified Dose
nausea 28.6% (placebo 0%)
alanine aminotransferase increased 14.3% (placebo 0%)
aspartate aminotransferase increased 14.3% (placebo 0%)
NCT06039579 · Phase 2 · combination · HIV · phase 2
Pre-specified Dose
vessel puncture site haematoma 28.6% (placebo 0%)
headache 14.3% (placebo 0%)
hypokalaemia 14.3% (placebo 0%)
NCT06039579 · Phase 2 · monotherapy · HIV · phase 2
1875 mg PiB
total bile acids increased 16.7% (placebo 0%)
abdominal pain 0% (placebo 0%)
activated partial thromboplastin time prolonged 0% (placebo 0%)
NCT05393271 · Phase 1 · monotherapy
625 mg PiB
gastroenteritis 16.7% (placebo 0%)
abdominal pain 0% (placebo 0%)
activated partial thromboplastin time prolonged 0% (placebo 0%)
NCT05393271 · Phase 1 · monotherapy
400 mg PiB
dry skin 16.7% (placebo 0%)
skin abrasion 16.7% (placebo 0%)
abdominal pain 0% (placebo 0%)
NCT05393271 · Phase 1 · monotherapy
300 mg + Midazolam (MDZ) PiB
somnolence 25% (placebo 0%)
dizziness 12.5% (placebo 0%)
feeling abnormal 12.5% (placebo 0%)
NCT05393271 · Phase 1 · combination
200 mg PiB
activated partial thromboplastin time prolonged 33.3% (placebo 0%)
blood triglycerides increased 16.7% (placebo 0%)
lipase increased 16.7% (placebo 0%)
NCT05393271 · Phase 1 · monotherapy
200 mg PiB
diarrhoea 33.3% (placebo 0%)
headache 33.3% (placebo 0%)
nausea 33.3% (placebo 0%)
NCT05393271 · Phase 1 · monotherapy
200 mg Tablet
medical device site dermatitis 16.7% (placebo 0%)
abdominal pain 0% (placebo 0%)
activated partial thromboplastin time prolonged 0% (placebo 0%)
NCT05393271 · Phase 1 · monotherapy
125 mg PiB
medical device site dermatitis 16.7% (placebo 0%)
abdominal pain 0% (placebo 0%)
activated partial thromboplastin time prolonged 0% (placebo 0%)
NCT05393271 · Phase 1 · monotherapy
25 mg PiB
blood creatine phosphokinase increased 16.7% (placebo 20%)
haematocrit decreased 16.7% (placebo 0%)
haemoglobin decreased 16.7% (placebo 0%)
NCT05393271 · Phase 1 · monotherapy
injection site nodule 66.1%
injection site pain 34.2%
genitourinary chlamydia infection 16.4%
NCT04994509 · Phase 3 · combination · HIV · phase 3
show 1 more result
injection site nodule 63.4%
injection site pain 56.4%
injection site erythema 17.3%
NCT04925752 · Phase 3 · combination · HIV · phase 3

Notes

  1. aPopulation comparability has not been reviewed for 9 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Dezecapavir

HIV-1 RNA -1.834 vs -0.176 placebo logDose Level 1
absolute change · log
Maximum change compared to Baseline (Day 1)
NCT06039579 · Phase 2 · combination · HIV · phase 2
show 2 more results
-1.797 vs -0.176 placebo logDose Level 2
Maximum change compared to Baseline (Day 1)
NCT06039579 · Phase 2 · combination · HIV · phase 2
-2.165 vs -0.176 placebo logPre-specified Dose
Maximum change compared to Baseline (Day 1)
NCT06039579 · Phase 2 · combination · HIV · phase 2
HIV-1 RNA -1.801 log @ 1.57wkDose Level 1
absolute change · log
No placebo or comparator arm
NCT06039579 · Phase 2 · combination · HIV · phase 2
show 2 more results
-1.75 log @ 1.57wkDose Level 2
NCT06039579 · Phase 2 · combination · HIV · phase 2
-2.165 log @ 1.57wkPre-specified Dose
NCT06039579 · Phase 2 · combination · HIV · phase 2

Lenacapavir (Yeztugo)

HIV-1 Incidence Per 100 PY 0 vs 2.018 F/TAF per 100 person year @ 52wk
event count · per 100 person year
NCT04994509 · Phase 3 · combination · HIV · phase 3
show 1 more result
0 vs 2.018 F/TAF per 100 person year @ 52wk
NCT04994509 · Phase 3 · combination · HIV · phase 3
HIV-1 Incidence Per 100 PY 0 per 100 person year @ 52wk
event count · per 100 person year
No placebo or comparator arm
NCT04994509 · Phase 3 · combination · HIV · phase 3
HIV-1 Incidence Rate Per 100 PY 0.103 per 100 person year @ 149wk
event rate · per 100 person year
No placebo or comparator arm
NCT04925752 · Phase 3 · combination · HIV · phase 3
show 1 more result
0.125 per 100 person year @ 149wk
NCT04925752 · Phase 3 · combination · HIV · phase 3
HIV-1 Incidence Rate Per 100 PY 0.103 vs 0.931 F/TDF per 100 person year @ 149wk
event rate · per 100 person year
NCT04925752 · Phase 3 · combination · HIV · phase 3

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Dezecapavir's landscape · Lenacapavir (Yeztugo)'s landscape